August 21, 2014 | Protalix Biotherapeutics is set to face a more competitive market for its treatment for Gaucher’s disease. The US Food & Drug Administration approved for marketing a new drug for the treatment of the genetic disease – Cerdelga made by Sanofi. Protalix’s flagship drug to treat Gaucher’s disease was also approved by the FDA for marketing and the company has a cooperation agreement with pharmaceutical giant Pfizer, which markets the drug everywhere except for Israel and Brazil. Gaucher’s disease is a genetic disease in which fatty substances accumulate in the cells and organs. Protalix was founded in 1993 by Yoseph Shaaltiel and is headquartered in Carmiel, Israel.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Israel Foodtech Firms Meet UK Retailers, Investors In London
April 17, 2024
Facebook comments